König, Alexander Otto

[["dc.bibliographiccitation.journal","Langenbeck's Archives of Surgery"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","König, Alexander"],["dc.contributor.author","Ghadimi, Michael"],["dc.date.accessioned","2022-09-01T09:51:31Z"],["dc.date.available","2022-09-01T09:51:31Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract\n \n Purpose\n VIPoma belongs to the group of neuroendocrine neoplasms. These tumours are located mostly in the pancreas and produce high levels of vasoactive intestinal peptide (VIP). In most cases, a metastatic state has already been reached at the initial diagnosis, with high levels of VIP leading to a wide spectrum of presenting symptoms. These symptoms include intense diarrhoea and subsequent hypopotassaemia but also cardiac complications, with life-threatening consequences. Treatment options include symptomatic therapy, systemic chemotherapy and targeted therapy, as well as radiation and surgery. Due to the low incidence of VIPoma, there are no prospective studies or evidence-based therapeutic standards to date.\n \n \n Methods\n To evaluate the possible impact of different therapy strategies, we performed literature research using PubMed.\n \n \n Results\n All possible treatment modalities for VIPoma have at least one of two therapy goals: antisecretory effects (symptom control) and antitumoural effects (tumour burden reduction). Symptomatic therapy is the most important in the emergency setting to rehydrate, balance electrolytes and stabilise the patient. Symptomatic therapy is also of great importance perioperatively. Somatostatin analogues play a major role in symptom control, although their efficiency is often limited. Chemotherapy may be effective in reaching stable disease for a certain time period, although its impact on symptom control is limited and often delayed. Among targeted therapy options, the usage of sunitinib appears to be the most effective in terms of symptom control and showing antitumoural effects at the same time. Experience with radiation is still limited; however, local ablative procedures seem to be promising options. Peptide receptor radiotherapy (PRRT) with radiolabelled somatostatin analogues (SSAs, 177Lu-DOTATATE) offers a targeted approach, especially in patients with high somatostatin receptor density. Surgery is the first-line therapy for nonmetastatic VIPoma. Additionally, if the resection of all visible tumour lesions is possible, the surgical approach seems preferable to other strategies in highly symptomatic patients. The role of surgery in very advanced stages where only tumour debulking is possible remains debatable. However, a high rate of immediate symptom control can be achieved by tumour debulking followed by somatostatin therapy, although the impact on survival remains unclear.\n \n \n Conclusion\n Surgery is the only curative option for nonmetastatic VIPoma. Additionally, surgery should be a first-line therapy option for highly symptomatic patients, especially if the resection of all tumour lesions (primary tumour and metastasis) is achievable. In frail patients, other modalities can be used."],["dc.identifier.doi","10.1007/s00423-022-02620-7"],["dc.identifier.pii","2620"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113988"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.eissn","1435-2451"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Treatment options of metastatic and nonmetastatic VIPoma: a review"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1280"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Theranostics"],["dc.bibliographiccitation.lastpage","1287"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Berger, Andreas W."],["dc.contributor.author","Schwerdel, Daniel"],["dc.contributor.author","Reinacher-Schick, Anke"],["dc.contributor.author","Uhl, Waldemar"],["dc.contributor.author","Algül, Hana"],["dc.contributor.author","Friess, Helmut"],["dc.contributor.author","Janssen, Klaus-Peter"],["dc.contributor.author","König, Alexander"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Gallmeier, Eike"],["dc.contributor.author","Bartsch, Detlef K."],["dc.contributor.author","Geissler, Michael"],["dc.contributor.author","Staib, Ludger"],["dc.contributor.author","Tannapfel, Andrea"],["dc.contributor.author","Kleger, Alexander"],["dc.contributor.author","Beutel, Alica"],["dc.contributor.author","Schulte, Lucas-Alexander"],["dc.contributor.author","Kornmann, Marko"],["dc.contributor.author","Ettrich, Thomas J."],["dc.contributor.author","Seufferlein, Thomas"],["dc.date.accessioned","2019-07-09T11:50:26Z"],["dc.date.available","2019-07-09T11:50:26Z"],["dc.date.issued","2019"],["dc.description.abstract","The most frequent malignancy of the pancreas is the pancreatic ductal adenocarcinoma (PDAC). Despite many efforts PDAC has still a dismal prognosis. Biomarkers for early disease stage diagnosis as a prerequisite for a potentially curative treatment are still missing. Novel blood-based markers may help to overcome this limitation. Methods: Prior to surgery plasma levels of thrombospondin-2 (THBS2), which was recently published as a novel biomarker, and CA19-9 from 52 patients with histologically proven PDAC were determined, circulating cell-free (cfDNA) was quantified. 15 patients with side-branch IPMNs without worrisome features and 32 patients with chronic pancreatitis served for comparison. Logit (logistic regression) models were used to test the performance of single biomarkers and biomarker combinations. Results: CA19-9 and THBS2 alone showed comparable c-statistics of 0.80 and 0.73, respectively, improving to 0.87 when combining these two markers. The c-statistic was further increased to 0.94 when combining CA19-9 and THBS2 with cfDNA quantification. This marker combination performed best for all PDAC stages but also for PDACs grouped by stage. The greatest improvement over CA19-9 was seen in the group of stage I PDAC, from 0.69 to 0.90 for the three marker combination. Conclusion:These data establish the combination of CA19-9, THBS2 and cfDNA as a composite liquid biomarker for non-invasive diagnosis of early-stage PDAC."],["dc.identifier.doi","10.7150/thno.29247"],["dc.identifier.pmid","30867830"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15940"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59773"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1838-7640"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.subject.ddc","610"],["dc.title","A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","234"],["dc.bibliographiccitation.issue","4_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","234"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Ettrich, Thomas Jens"],["dc.contributor.author","Berger, Andreas Wolfgang"],["dc.contributor.author","Schwerdel, Daniel"],["dc.contributor.author","Reinacher-Schick, Anke C."],["dc.contributor.author","Uhl, Waldemar"],["dc.contributor.author","Alguel, Hana"],["dc.contributor.author","Friess, Helmut"],["dc.contributor.author","Koenig, Alexander"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Gallmeier, Eike"],["dc.contributor.author","Bartsch, Detlef K."],["dc.contributor.author","Geissler, Michael"],["dc.contributor.author","Staib, Ludger"],["dc.contributor.author","Tannapfel, Andrea"],["dc.contributor.author","Kleger, Alexander"],["dc.contributor.author","Seufferlein, Thomas"],["dc.date.accessioned","2020-12-10T18:41:37Z"],["dc.date.available","2020-12-10T18:41:37Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1200/JCO.2019.37.4_suppl.234"],["dc.identifier.eissn","1527-7755"],["dc.identifier.issn","0732-183X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77632"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","A blood-based assay for diagnosis of early-stage pancreatic cancer."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","4128"],["dc.bibliographiccitation.issue","15_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","4128"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Uhl, Waldemar"],["dc.contributor.author","Ettrich, Thomas Jens"],["dc.contributor.author","Reinacher-Schick, Anke C."],["dc.contributor.author","Algül, Hana"],["dc.contributor.author","Friess, Helmut"],["dc.contributor.author","Kornmann, Marko"],["dc.contributor.author","Koenig, Alexander"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Wittel, Uwe A"],["dc.contributor.author","Gallmeier, Eike"],["dc.contributor.author","Wille, Kai"],["dc.contributor.author","Geissler, Michael"],["dc.contributor.author","Schimanski, Carl Christoph"],["dc.contributor.author","Prasnikar, Nicole"],["dc.contributor.author","Tannapfel, Andrea"],["dc.contributor.author","Perkhofer, Lukas"],["dc.contributor.author","Berger, Andreas W."],["dc.contributor.author","Seufferlein, Thomas"],["dc.date.accessioned","2020-12-10T18:41:36Z"],["dc.date.available","2020-12-10T18:41:36Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1200/JCO.2019.37.15_suppl.4128"],["dc.identifier.eissn","1527-7755"],["dc.identifier.issn","0732-183X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77625"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","NEONAX trial: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase II study of the AIO pancreatic cancer group (AIO-PAK-0313)—Safety interim analysis."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","175628482110511"],["dc.bibliographiccitation.journal","Therapeutic Advances in Gastroenterology"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","König, Alexander"],["dc.contributor.author","Hartmann, Amelie"],["dc.contributor.author","Schuppert, Frank"],["dc.contributor.author","Seif Amir Hosseini, Ali"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Ghadimi, Michael"],["dc.date.accessioned","2022-01-11T14:08:01Z"],["dc.date.available","2022-01-11T14:08:01Z"],["dc.date.issued","2021"],["dc.description.abstract","VIPoma, a neuroendocrine tumour mostly occurring in the human pancreas and producing high levels of vasoactive intestinal peptide, is a rare disease that presents with a wide spectrum of symptoms, including intense diarrhoea, hypokalaemia, and cardiac complications, with life-threatening consequences. In most cases, metastatic lesions are present at VIPoma diagnosis. Treatment options include symptomatic therapy, chemotherapy, radiation and surgery. Due to its low incidence, there are no evidence-based therapy recommendations to date. Here, we present a case of a 39-year-old woman with severe symptoms due to VIPoma of the pancreas with diffuse hepatic metastasis, who underwent simultaneous resection of the primary tumour, extensive liver resection and radiofrequency ablation. The patient was released in good health and was recurrence-free during 12 months surveillance. According to the existing literature and our own experience, surgical procedures appear to be the most promising therapy option for cases with diffuse hepatic metastasis, offering patients relief from their symptoms and (chemo)therapy-free time."],["dc.identifier.doi","10.1177/17562848211051132"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/97916"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-507"],["dc.relation.issn","1756-2848"],["dc.rights","CC BY-NC 4.0"],["dc.title","Surgical treatment of metastatic VIPoma: a case report"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1463"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","International Journal of Colorectal Disease"],["dc.bibliographiccitation.lastpage","1469"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Lowes, Markus"],["dc.contributor.author","Kleiss, Mathias"],["dc.contributor.author","Lueck, Rainer"],["dc.contributor.author","Detken, Sven"],["dc.contributor.author","König, Alexander Otto"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Stanek, Kathrin"],["dc.contributor.author","Langer, Claus"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Homayounfar, Kia"],["dc.date.accessioned","2019-07-09T11:44:24Z"],["dc.date.available","2019-07-09T11:44:24Z"],["dc.date.issued","2017"],["dc.description.abstract","PURPOSE: Multidisciplinary tumor boards (MDT) have been advocated as standard of care in modern oncology. German guidelines for metastasized colorectal cancer (mCRC) recommend MDT discussion of colon cancer patients after completion of primary tumor therapy but stage IV colon cancer as well as rectal cancer patients prior to any therapy. In this health care research study, we evaluated application and decisional consequences of this approach in clinical routine. METHODS: All major institutions providing oncological care in southern Lower Saxony and Northern Hesse (N = 11) were invited. Patients with mCRC diagnosed between 01/2011 and 12/2013 were eligible. Data were collected using a standardized patient report form and stored in a GCP-conform EDC-system (secuTrial®). RESULTS: A university medical center, four teaching hospitals, one communal hospital, and three oncological focus practices participated in the study. In total, 470 patients with a median age of 70 years were enrolled. Guideline conform MDT discussion was performed in 63% of operated colon cancer patients, 38% of stage IV colon cancer patients and 47% of rectal cancer patients, respectively. Resection of metastases was performed in 41% of cases. Patients ≥70 years (n = 250) received significantly more often treatment following MDT discussion (86 versus 64%, p = 0.0002). Not the resection rate (48 versus 57%, p = 0.1574) but indication for preoperative chemotherapy (57 versus 33%, p = 0.0056) significantly differed when patients with single organ metastases experienced MDT discussion. CONCLUSIONS: MDT discussion is not as established as advocated by national guidelines. Treatment decisions differ especially in older patients and those with single organ metastases."],["dc.identifier.doi","10.1007/s00384-017-2871-z"],["dc.identifier.pmid","28779354"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14738"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59003"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","The utilization of multidisciplinary tumor boards (MDT) in clinical routine: results of a health care research study focusing on patients with metastasized colorectal cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Rühlmann, Felix"],["dc.contributor.author","Krause, Tanja"],["dc.contributor.author","Bernhardt, Markus"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","König, Alexander"],["dc.contributor.author","Kleiß, Mathias"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2021-04-14T08:27:35Z"],["dc.date.available","2021-04-14T08:27:35Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1038/s41598-020-57930-x"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82341"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","2045-2322"],["dc.title","CA19-9 for detecting recurrence of pancreatic cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0153278"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Koenig, Alexander O."],["dc.contributor.author","Schirmer, Markus"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Bernhardt, Markus"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T10:15:34Z"],["dc.date.available","2018-11-07T10:15:34Z"],["dc.date.issued","2016"],["dc.description.abstract","Introduction Anti-EGFR targeted therapy is of increasing importance in advanced colorectal cancer and prior KRAS mutation testing is mandatory for therapy. However, at which occasions this should be performed is still under debate. We aimed to assess in patients with locally advanced rectal cancer whether there is intra-specimen KRAS heterogeneity prior to and upon preoperative chemoradiotherapy (CRT), and if there are any changes in KRAS mutation status due to this intervention. Materials and Methods KRAS mutation status analyses were performed in 199 tumor samples from 47 patients with rectal cancer. To evaluate the heterogeneity between different tumor areas within the same tumor prior to preoperative CRT, 114 biopsies from 34 patients (mean 3 biopsies per patient) were analyzed (pre-therapeutic intratumoral heterogeneity). For the assessment of heterogeneity after CRT residual tumor tissue (85 samples) from 12 patients (mean 4.2 tissue samples per patient) were analyzed (post-therapeutic intratumoral heterogeneity) and assessment of heterogeneity before and after CRT was evaluated in corresponding patient samples (interventional heterogeneity). Primer extension method (SNaPshot (TM)) was used for initial KRAS mutation status testing for Codon 12, 13, 61, and 146. Discordant results by this method were reevaluated by using the FDA-approved KRAS Pyro Kit 24, V1 and the RAS Extension Pyro Kit 24, V1 Kit (therascreen (R) KRAS test). Results For 20 (43%) out of the 47 patients, a KRAS mutation was detected. With 12 out of 20, the majority of these mutations affected codon 35. We did not obtained evidence that CRT results in changes of the KRAS mutation pattern. In addition, no intratumoral heterogeneity in the KRAS mutational status could be proven. This was true for both the biopsies prior to CRT and the resection specimens thereafter. The discrepancy observed in some samples when using the SNaPshot (TM) assay was due to insufficient sensitivity of this technique upon massive tumor regression by CRT as application of the therascreen (R) KRAS test revealed concordant results. Conclusion Our results indicate that the KRAS mutation status at the primary tumor site of rectal cancer is homogenous. Its assessment for therapeutic decisions is feasible in pre-therapeutic biopsies as well as in post-therapeutic resected specimens. The amount of viable tumor cells seems to be an important determinant for assay sensitivity and should thus be considered for selection of the analytical method."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2016"],["dc.identifier.doi","10.1371/journal.pone.0153278"],["dc.identifier.isi","000373891000040"],["dc.identifier.pmid","27064574"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13201"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40835"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Heterogeneity of KRAS Mutation Status in Rectal Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e0239806"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Bernhardt, Markus"],["dc.contributor.author","Nietert, Manuel"],["dc.contributor.author","König, Alexander"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","Schirmer, Markus A."],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Reuter-Jessen, Kirsten"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.editor","Deb, Sumitra"],["dc.date.accessioned","2021-04-14T08:31:16Z"],["dc.date.available","2021-04-14T08:31:16Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1371/journal.pone.0239806"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17654"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83536"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1932-6203"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","KRAS mutation status concordance between the primary tumor and the corresponding metastasis in patients with rectal cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]